Skip to main content
Premium Trial:

Request an Annual Quote

SIRS-Lab Declares Insolvency, Seeks Investor to Commercialize Sepsis Test

NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.

The company embarked on a clinical trial of Vyoo, its PCR- and array-based sepsis test, in 2011, and said this week that it completed the trial at the end of last year.

The trial enrolled 1,000 patients at 13 centers across Germany. The company said its technology can determine what pathogens are present in a sample and what antibiotic resistance they harbor within seven hours, allowing clinicians to begin therapies faster than with standard diagnostic methods.

But to bring the test to market, the company said it needs further investment.

The District Court of Gera in Germany has appointed Rolf Rattunde of Leonhardt Rechtsanwälte Erfurt as the company's provisional insolvency administrator.

"In order to bring the test to market, further investments are necessary upon which the current shareholders cannot agree," Rattunde said in a statement. "Therefore, we are now searching for investors for this very interesting diagnostics company. The first meetings with management and employees made me very confident to proceed with operations."

SIRS-Lab has 30 employees.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.